证券代码：600332 证券简称：白云山 公告编号：2025－077 广州白云山医药集团股份有限公司 第九届董事会第三十次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届董事会第三十次会 议（"会议"）通知于 2025 年 10 月 15 日以书面及电邮方式发出，于 2025 年 10 月 28 日以通讯表决的方式召开。本次会议应出席会议董事 10 人，实际出席会 议董事 10 人。会议的召集、召开符合《公司法》及《公司章程》的规定。 经董事审议、表决，会议审议通过如下议案： 一、本公司 2025 年第三季度报告 表决结果：同意票 10 票、反对票 0 票、弃权票 0 票，审议通过本议案。 本议案已经本公司董事会审计委员会 2025 年第 4 次会议审议通过。 二、关于修订《广州白云山医药集团股份有限公司董事会审核委员会实施 细则》相关条款的议案（全文载于上海证券交易所网站） 表决结果：同意票 10 票、反对票 0 票、弃权票 0 票，审议通过本议案。 三、关于修 ...

格隆汇10月28日丨白云山公告，2025年第三季度营收为197.71亿元，同比增长9.74%；净利润为7.94亿 元，同比增长30.28%。前三季度营收为616.06亿元，同比增长4.31%；净利润为33.1亿元，同比增长 4.78%。 ...

Financial Performance - The company's operating revenue for the third quarter reached CNY 19,771,447,682, representing a year-on-year increase of 9.74%[7] - Total profit for the quarter was CNY 1,093,686,290, marking a significant increase of 40.82% compared to the same period last year[7] - Net profit attributable to shareholders was CNY 793,911,091, reflecting a growth of 30.28% year-on-year[7] - Basic earnings per share for the quarter stood at CNY 0.488, an increase of 30.28% compared to the previous year[7] - Total operating revenue for the first three quarters of 2025 reached ¥61.61 billion, an increase of 4.2% compared to ¥59.06 billion in the same period of 2024[31] - Total operating costs for the first three quarters of 2025 were ¥57.78 billion, up from ¥55.41 billion in 2024, reflecting a growth of 4.3%[31] - Net profit for the first three quarters of 2025 was ¥3.40 billion, compared to ¥3.29 billion in 2024, representing an increase of 3.3%[32] - The company reported a total profit of ¥4.18 billion for the first three quarters of 2025, compared to ¥4.01 billion in 2024, indicating a growth of 4.4%[32] - Total comprehensive income for the first three quarters of 2025 reached CNY 3,391,689,202.13, compared to CNY 3,294,891,696.02 in the same period of 2024, reflecting an increase of approximately 2.95%[33] - Basic and diluted earnings per share for the first three quarters of 2025 were CNY 2.036, up from CNY 1.943 in 2024, representing an increase of about 4.79%[33] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 83,169,260,288, up 1.82% from the end of the previous year[9] - Shareholders' equity attributable to the company increased by 5.58% to CNY 37,906,307,061 compared to the previous year-end[9] - The company's total liabilities as of September 30, 2025, amounted to ¥43.19 billion, a slight decrease from ¥43.91 billion at the end of 2024[29] - Current liabilities totaled ¥37.74 billion as of September 30, 2025, down from ¥38.92 billion at the end of 2024, indicating a reduction of 3.0%[29] - Non-current liabilities increased to ¥5.45 billion as of September 30, 2025, compared to ¥4.99 billion at the end of 2024, marking a rise of 9.2%[29] - The company's retained earnings reached ¥23.82 billion as of September 30, 2025, up from ¥21.82 billion at the end of 2024, reflecting an increase of 9.2%[29] Cash Flow - The net cash flow from operating activities showed a significant decline, amounting to (CNY 1,971,973,586), a decrease of 162.45% year-on-year[7] - Cash inflow from operating activities totaled CNY 54,539,125,266.81 in 2025, slightly down from CNY 55,018,985,333.25 in 2024, indicating a decrease of approximately 0.87%[35] - Cash outflow from operating activities increased to CNY 56,511,098,852.89 in 2025, compared to CNY 55,770,347,563.45 in 2024, marking an increase of about 1.33%[36] - Net cash flow from operating activities for the first three quarters of 2025 was negative CNY 1,971,973,586.08, worsening from negative CNY 751,362,230.20 in 2024[36] - Cash inflow from investment activities significantly rose to CNY 7,031,185,327.43 in 2025, compared to CNY 698,340,504.82 in 2024, showing a substantial increase of approximately 909.06%[36] - Net cash flow from investment activities was negative CNY 3,421,114,034.78 in 2025, an improvement from negative CNY 4,239,805,542.16 in 2024[36] - Cash inflow from financing activities increased to CNY 10,783,209,577.82 in 2025, compared to CNY 8,534,366,363.04 in 2024, reflecting an increase of about 26.19%[37] - Net cash flow from financing activities for the first three quarters of 2025 was positive CNY 1,006,364,008.77, compared to CNY 587,309,332.49 in 2024, indicating an increase of approximately 71.14%[37] - The ending cash and cash equivalents balance for the first three quarters of 2025 was CNY 11,920,281,249.10, down from CNY 15,424,695,678.20 in 2024, representing a decrease of about 22.73%[37] Current Assets and Inventory - As of September 30, 2025, total current assets amounted to CNY 60,436,093,365.81, an increase from CNY 57,762,228,309.37 as of December 31, 2024, reflecting a growth of approximately 2.92%[24] - The company's cash and cash equivalents decreased to CNY 13,708,456,362.90 from CNY 18,273,150,112.58, representing a decline of about 25.5%[24] - Accounts receivable increased significantly to CNY 19,134,817,688.17, up from CNY 15,725,982,661.17, indicating a growth of approximately 21.5%[24] - Total non-current assets decreased to CNY 22,733,166,922.22 from CNY 23,921,383,211.27, a decline of about 4.97%[25] - The total assets of the company reached CNY 83,169,260,288.03, compared to CNY 81,683,611,520.64 at the end of 2024, marking an increase of approximately 1.82%[25] - The company reported a significant increase in inventory, which decreased to CNY 11,080,685,715.39 from CNY 12,811,902,453.79, reflecting a decline of about 13.5%[24] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥443.72 million, a decrease of 23.3% from ¥578.51 million in the same period of 2024[31] Market and Strategic Plans - The company plans to enhance market expansion efforts and invest in new product development to drive future growth[17] Other Information - The company has not disclosed any new product developments or technological advancements during the reporting period[22] - There were no changes in the participation of major shareholders in financing and securities lending activities[21] - The company has not reported any mergers or acquisitions in the recent period[22] - There are no significant reminders or additional important information regarding the company's operational situation during the reporting period[22]

白云山10月28日公告，2025年第三季度实现营业收入197.71亿元，同比增长9.74%；归属于上市公司股 东的净利润7.94亿元，同比增长30.28%；基本每股收益0.488元。前三季度实现营业收入616.06亿元，同 比增长4.31%；归属于上市公司股东的净利润33.1亿元，同比增长4.78%；基本每股收益2.036元。 ...

Financial Performance - The company's operating revenue for the third quarter reached CNY 19,771,447,682, representing a year-on-year increase of 9.74%[6] - The total profit for the quarter was CNY 1,093,686,290, marking a significant increase of 40.82% compared to the same period last year[6] - The net profit attributable to shareholders was CNY 793,911,091, which is a 30.28% increase year-on-year[6] - The net profit after deducting non-recurring gains and losses was CNY 663,826,285, reflecting a 28.90% increase compared to the previous year[6] - The basic earnings per share for the quarter was CNY 0.488, up 30.28% from the same period last year[7] - Total operating revenue for the first three quarters of 2025 reached ¥61.61 billion, an increase from ¥59.06 billion in the same period of 2024, representing a growth of approximately 4.25%[24] - Net profit for the first three quarters of 2025 was ¥3.40 billion, slightly higher than ¥3.29 billion in 2024, showing an increase of about 3.39%[25] - The net profit attributable to the parent company shareholders for the first three quarters of 2025 was approximately ¥3.31 billion, an increase from ¥3.16 billion in the same period of 2024, representing a growth of about 4.8%[26] - The total comprehensive income for the first three quarters of 2025 reached approximately ¥3.39 billion, compared to ¥3.29 billion in 2024, indicating an increase of around 3.2%[26] - The basic and diluted earnings per share for the current period were both ¥2.036, up from ¥1.943 in the previous year, reflecting an increase of approximately 4.8%[26] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 83,169,260,288, an increase of 1.82% from the end of the previous year[7] - The total current assets as of September 30, 2025, amounted to ¥60,436,093,365.81, an increase from ¥57,762,228,309.37 as of December 31, 2024[18] - Total non-current assets were ¥8,277,056,423.59 as of September 30, 2025, compared to ¥9,561,184,920.12 at the end of 2024[18] - Total non-current assets decreased from ¥23.92 billion to ¥22.73 billion, a decline of about 5.00%[20] - Total liabilities decreased from ¥43.91 billion to ¥43.19 billion, a reduction of approximately 1.64%[20] - Total equity increased from ¥37.77 billion to ¥39.98 billion, reflecting a growth of about 5.83%[20] Cash Flow - The cash flow from operating activities showed a negative net amount of CNY (1,971,973,586), a decrease of 162.45% year-to-date[7] - The net cash flow from operating activities for the first three quarters of 2025 was negative at approximately (¥1.97 billion), worsening from (¥751 million) in the same period of 2024[29] - Cash inflows from investment activities totaled approximately ¥7.03 billion, significantly higher than ¥698 million in the previous year, marking a substantial increase[30] - The net cash flow from financing activities for the first three quarters of 2025 was approximately ¥1.01 billion, compared to ¥587 million in 2024, indicating an increase of about 71.2%[30] - The total cash and cash equivalents at the end of the period were approximately ¥11.92 billion, down from ¥15.42 billion at the end of the previous year, a decrease of about 22.1%[30] - The company reported a cash outflow from operating activities totaling approximately ¥56.51 billion, an increase from ¥55.77 billion in the previous year[29] Shareholder Information - Total number of common shareholders at the end of the reporting period was 101,673[15] - Guangzhou Pharmaceutical Group Co., Ltd. holds 732,305,103 shares, representing 45.04% of total shares[15] - HKSCC Nominees Limited holds 219,785,142 shares, representing 13.52% of total shares[15] - The company reported no significant changes in major shareholders' participation in margin trading and securities lending[16] Operational Insights - The company plans to continue expanding its market presence and enhancing product offerings to meet growing market demands[12] - There are no applicable reminders for investors regarding the company's operational situation during the reporting period[17] Costs and Expenses - Total operating costs for the first three quarters of 2025 were ¥57.78 billion, up from ¥55.41 billion in 2024, indicating an increase of about 4.28%[25] - Research and development expenses for the first three quarters of 2025 amounted to ¥443.72 million, down from ¥578.51 million in 2024, a decrease of approximately 23.26%[25] - The company reported a significant increase in accounts payable, rising from ¥11.73 billion to ¥12.89 billion, an increase of approximately 9.88%[25] - Accounts receivable increased to ¥19,134,817,688.17 from ¥15,725,982,661.17 year-over-year[18] - Inventory decreased to ¥11,080,685,715.39 from ¥12,811,902,453.79 year-over-year[18] Non-Recurring Gains - Non-recurring gains for the quarter totaled CNY 130,084,806, with significant contributions from government subsidies and fair value changes of financial assets[10] Accounting Standards - The company has not applied new accounting standards or interpretations for the first time in 2025[31]

广州白云山医药集团股份有限公司 审计委员会年报工作规程 （经公司 2025 年 10 月 28 日召开的第九届董事会第三十次会议 审议通过） 第六条 年审会计师进场后，审计委员会应加强与年审会计 师的沟通，在年审会计师出具初步审计意见后再次审阅公司财 务会计报表。 第七条 年审会计师对公司年度财务报告审计完成后，应在 提交董事会审议前提交公司审计委员会审核，并由审计委员会 进行表决，经审计委员会成员的过半数通过并形成决议后提交 公司董事会审核。 第八条 审计委员会在向董事会提交年度财务报告的同时， 应向董事会提交会计师事务所从事本年度公司审计工作的总结 报告。 第九条 审计委员会对在公司年报编制过程中所获知的信 息负有保密义务，严防泄露内幕信息、进行内幕交易等违法违 规行为的发生。在公司年度审计过程中，审计委员会应督促会 计师事务所及相关人员履行保密义务，不得擅自披露有关信息。 -2- 第一条 为强化广州白云山医药集团股份有限公司（以下简 称"公司"）董事会辖下审计委员会（以下简称"审计委员会"） 决策功能，提高内部审计工作质量和信息披露质量，充分发挥 审计委员会的监督作用，根据中国证券监督管理委员会的有关 ...

广州白云山医药集团股份有限公司 独立董事制度 （经公司 2025 年 10 月 28 日召开的第九届董事会第三十次会议 审议通过） 第一章 总则 第一条 为进一步完善广州白云山医药集团股份有限公司 （以下简称"公司"）治理结构，促进公司规范运作，充分发挥 独立董事的积极作用，认真履行职责，维护公司整体利益，根 据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司治理准则》《上市公司独立董事管理办法》《上海证券 交易所股票上市规则》及《香港联合交易所有限公司证券上市 规则》等规定及《广州白云山医药集团股份有限公司章程》（以 下简称"《公司章程》"）的规定，特制定本独立董事制度（以 下简称"本制度"）。 第二条 独立董事是指不在公司担任除董事外的其他职务， 并与公司及其主要股东、实际控制人不存在直接或者间接利害 关系，或者其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实 际控制人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务， 应当按照法律、行政法规、公司上市所在地证券监督管理机构 -1- （四）具有五年以上履行独立董事职责所必需 ...

广州白云山医药集团股份有限公司 董事会秘书工作细则 （经公司 2025 年 10 月 28 日召开的第九届董事会第三十次会议 审议通过） 第一章 总则 第一条 为了促进广州白云山医药集团股份有限公司（以下 简称"公司"）的规范运作，明确董事会秘书的职责权限，充 分发挥董事会秘书的作用，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》《上海 证券交易所股票上市规则》《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》《香港联合交易所有限公司证券 上市规则》《广州白云山医药集团股份有限公司章程》（以下 简称"《公司章程》"）及相关法律、法规及其他规范性文件 的规定，特制定本细则。 第二条 公司设董事会秘书，董事会秘书为公司高级管理人 员。 第三条 董事会秘书是公司与公司上市所在地证券交易所、 境内外监管机构之间的指定联络人，负责以公司名义办理信息 披露、公司治理、投资者关系管理、股权管理等其相关职责范 围内的事务，履行法定报告义务，配合证券监管部门对公司的 检查和调查，协调落实各项监管要求。 -1- 第四条 公司应当在原任董事会秘书离职后三个月内聘任 董事会秘书。 第五 ...

广州白云山医药集团股份有限公司 信息披露暂缓与豁免业务管理制度 第三条 公司和其他信息披露义务人应当真实、准确、完整、及 时、公平地披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、 误导投资者，不得实施内幕交易、操纵市场等违法行为。 （经公司 2025 年 10 月 28 日召开的第九届董事会第三十次董事会会 议审议通过） 第一章 总 则 第一条 为规范广州白云山医药集团股份有限公司（以下简称"公 司"）及相关信息披露义务人信息披露暂缓与豁免行为，保护投资者 合法权益，根据《中华人民共和国证券法》《上市公司信息披露管理 制度》《上市公司信息披露暂缓与豁免管理规定》《上海证券交易所股 票上市规则》及《公司章程》等规定，结合公司实际情况，特制定本 制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告， 在定期报告、临时报告中豁免披露中国证券监督管理委员会和上海证 券交易所规定或者要求披露的内容，适用本制度。 第四条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、 豁免事项，履行内部审核程序后实施。 第五条 公司暂缓或者豁免的披露不得违反香港联合交易所有限 公司监管规则。 第二章 信息披露暂缓与豁 ...

广州白云山医药集团股份有限公司 关于防范控股股东及关联方资金占用 的管理办法 （经本公司 2025 年 10 月 28 日召开的第九届董事会第三十 次会议审议通过） 第一章 总则 第一条 为维护公司资产完整，进一步加强对公司资金 往来的有效监管，防范控股股东、实际控制人及其他关联方 占用公司资金，维护投资者合法权益，广州白云山医药集团 股份有限公司（以下简称"公司"）根据《中华人民共和国 公司法》《上市公司治理准则》《国务院关于进一步提高上市 公司质量的意见》《上市公司监管指引第 8 号——上市公司 资金往来、对外担保的监管要求》和《公司章程》等规定， 结合公司的实际情况，特制订本办法。 第二条 资金占用包括经营性资金占用和非经营性资 金占用： （一）经营性资金占用是指控股股东、实际控制人及其 他关联方通过采购、销售等生产经营环节的关联交易产生的 资金占用； （二）非经营性资金占用是指为控股股东、实际控制人 及其他关联方垫付的工资、福利、保险、广告等费用和其他 支出，代控股股东、实际控制人及其他关联方偿还债务而支 付资金，有偿或无偿、直接或间接拆借给控股股东、实际控 制人及其他关联方资金，为控股股东、实际控制 ...